Dr. Reddy’s Forays into Hormone Replacement Therapy Segment with Acquisition of Progynova® and Cyclo- Progynova® in India

Dr. Reddy’s Laboratories Ltd. has acquired the trademarks of specialty brands, Progynova® and Cyclo- Progynova® and related assets, for India from Mercury Pharma Group Limited, a UK-headquartered specialty pharmaceutical company. Progynova® is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo- Progynova® is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. Progynova® is the #1 Brand in the Estradiol represented pharmaceutical market (RPM), with strong physician equity and brand recall in India. The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment.